Skip to main content

Table 1 Clinicopathological characteristics of the patients with male breast cancer

From: Hormone signaling via androgen receptor affects breast cancer and prostate cancer in a male patient: A case report

age TNM classification histology ER (%) PgR (%) HER2 (FISH) AR (%) Ki-67 (%) Histological grade Radiation Adjuvant therapy Follow up (months), Outcome
47 T2N0M0 IDC 99 80 1+ 60 50 2 (2/3/1) pre; TC (4)
post; cape+TAM
8
58 T1bN0M0 IDC 99 40 1+ 20 20 2 (3/2/1) post; TAM 27
63 T1aN0M0 IDC 99 80 1+ 90 10 1 (2/2/1) 60Gy/30fr
(WBRT)
48
63 T1cN0M0 IDC 90 80 2+
(1.54)
95 70 3 (3/2/3) post; TAM 90
69 T3N3aM0 IDC 90 0 1+ 95 10 3 (3/3/2) post; CEF (2)
MBC; TOR + 5’DFUR
wPTX
76
deceased
72 T2N3aM0 IDC 99 90 2+
(2.26)
90 30 2 (3/2/1) 50Gy/25fr
(PMRT)
pre; wPTX + trastuzumab (4)
post; TAM + trastuzumab (13)
14
74 T2N0M0 IDC 95 95 0 95 15 1 (2/2/1) post; TAM 56
Local recurrence, bone meta at 24 months
74 T2N0M0 mucinous 80 80 0 80 < 1 post; TAM 57
\